Lunit Inc. (KOSDAQ:328130)

South Korea flag South Korea · Delayed Price · Currency is KRW
40,250
-1,650 (-3.94%)
At close: Feb 6, 2026
-43.23%
Market Cap1.18T -38.6%
Revenue (ttm)76.69B +94.0%
Net Income-88.24B
EPS-3,513.66
Shares Out29.26M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume343,829
Average Volume511,227
Open41,300
Previous Close41,900
Day's Range39,450 - 42,250
52-Week Range34,150 - 77,100
Beta1.20
RSI48.49
Earnings DateFeb 11, 2026

About Lunit

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such a... [Read more]

Sector Technology
Founded 2013
Employees 307
Stock Exchange KOSDAQ
Ticker Symbol 328130
Full Company Profile

Financial Performance

In 2024, Lunit's revenue was 54.18 billion, an increase of 116.03% compared to the previous year's 25.08 billion. Losses were -82.42 billion, 124.0% more than in 2023.

Financial Statements